Shares of Assembly Biosciences Inc (NASDAQ:ASMB) fell 9.3% during trading on Thursday . The stock traded as low as $19.37 and last traded at $19.96. 878,337 shares traded hands during trading, an increase of 203% from the average session volume of 289,577 shares. The stock had previously closed at $22.00.
Several brokerages have recently commented on ASMB. Chardan Capital restated a “neutral” rating on shares of Assembly Biosciences in a research report on Sunday, October 28th. Zacks Investment Research upgraded shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, October 9th. BidaskClub upgraded shares of Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research report on Tuesday, January 1st. Leerink Swann began coverage on shares of Assembly Biosciences in a research report on Monday, November 19th. They set an “outperform” rating and a $45.00 price objective on the stock. Finally, B. Riley upgraded shares of Assembly Biosciences from a “neutral” rating to a “buy” rating and set a $42.00 price objective on the stock in a research report on Monday, October 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $52.00.
The firm has a market cap of $560.19 million, a PE ratio of -8.75 and a beta of 1.42.
Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.01) by $0.14. The company had revenue of $4.29 million for the quarter, compared to the consensus estimate of $3.21 million. Assembly Biosciences had a negative net margin of 469.91% and a negative return on equity of 50.63%. On average, analysts forecast that Assembly Biosciences Inc will post -4 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Rhumbline Advisers grew its stake in shares of Assembly Biosciences by 9.4% in the 2nd quarter. Rhumbline Advisers now owns 16,545 shares of the biopharmaceutical company’s stock worth $649,000 after buying an additional 1,420 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in shares of Assembly Biosciences by 3.3% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 36,366 shares of the biopharmaceutical company’s stock worth $1,426,000 after buying an additional 1,166 shares in the last quarter. BlackRock Inc. grew its stake in shares of Assembly Biosciences by 15.2% in the 2nd quarter. BlackRock Inc. now owns 1,240,752 shares of the biopharmaceutical company’s stock worth $48,650,000 after buying an additional 163,252 shares in the last quarter. FMR LLC purchased a new position in shares of Assembly Biosciences in the 2nd quarter worth $3,180,000. Finally, MetLife Investment Advisors LLC purchased a new position in shares of Assembly Biosciences in the 2nd quarter worth $282,000. Institutional investors own 84.94% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.thelincolnianonline.com/2019/01/12/assembly-biosciences-asmb-shares-down-9-3.html.
About Assembly Biosciences (NASDAQ:ASMB)
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
Featured Article: What is Cost of Debt?
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.